2003–2020年中国仿制药上市和新药市场独占期研究

doi:10.5246/jcps.2024.01.006

中国药学(英文版) ›› 2024, Vol. 33 ›› Issue (1): 57-62.DOI: 10.5246/jcps.2024.01.006

• 【药事管理与临床药学专栏】 • 上一篇下一篇

2003–2020年中国仿制药上市和新药市场独占期研究

周从亚¹, 黄涛¹, 顾佳慧¹, 李黄倩玉², 史录文¹^,², 管晓东¹^,²^,^*()

^1. 北京大学药学院药事管理与临床药学系, 北京 100191
^2. 北京大学医药管理国际研究中心, 北京 100191

收稿日期:2023-10-03 修回日期:2023-11-12 接受日期:2023-12-15 出版日期:2024-01-31 发布日期:2024-01-31
通讯作者: 管晓东

Generic development and market exclusivity period in China: an analysis from 2003 to 2020

Congya Zhou¹, Tao Huang¹, Jiahui Gu¹, Huangqianyu Li², Luwen Shi¹^,², Xiaodong Guan¹^,²^,^*()

¹ Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
² International Research Center for Medicinal Administration, Peking University, Beijing 100191, China

Received:2023-10-03 Revised:2023-11-12 Accepted:2023-12-15 Online:2024-01-31 Published:2024-01-31
Contact: Xiaodong Guan

摘要/Abstract

摘要：

中国近期提出给予新药、孤儿药和儿科药物6年的数据保护期, 以鼓励相关药物的研发创新。本研究评估了2003至2020年在中国批准上市的356种新小分子药物的仿制药上市情况和市场独占期。所有新药中, 155个(43.5%)新药有仿制药上市, 市场独占期中位数为5.6(四分位数: 2.4–9.4)年。进口药物、口服缓释药物和神经系统药物比其它药物的仿制药上市比例更高(P < 0.001, P = 0.039, P < 0.001)。国产药品的市场独占期中位数比进口药品更长(8.4 vs 5.7年)。市场独占期中位数从抗肿瘤和免疫调节剂的3.6年到消化道和代谢药物的6.8年不等。如果获得6年的数据保护期, 新药的市场独占期中位数预计将增加一倍。较长的市场独占期可能降低患者药品可及性, 政府在制定相关政策时应考虑在鼓励创新和确保药品可及性间寻求平衡。

关键词: 仿制药, 市场独占期, 小分子药物, 新药研发

Abstract:

China recently proposed a 6-year regulatory exclusivity period to incentivize research and development in new drugs, orphan drugs, and pediatric drugs. Our study assessed the generic entry status and the duration of market exclusivity for 356 new small-molecule drugs approved in China from 2003 to 2020. Of these, 155 drugs (43.5%) experienced generic entry, with a median market exclusivity period of 5.6 years (interquartile range: 2.4–9.4). Imported drugs, oral common-release agents, and drugs for the nervous system were more prone to generic entry (P < 0.001, P = 0.039, and P < 0.001, respectively). Domestic new drugs had a longer median market exclusivity (8.4 years) compared to imported drugs (5.7 years). Market exclusivity varied from 3.6 years for antineoplastic and immunomodulating agents to 6.8 years for drugs for the alimentary tract and metabolism. If the proposed 6-year regulatory exclusivity is implemented, the market exclusivity duration for new drugs is anticipated to double. It is essential for the government to carefully weigh the impact of such policies on balancing innovation incentives and ensuring drug affordability.

Key words: Generic drug, Market exclusivity period, Small molecule drugs, New drug development

Supporting: /attached/file/20240304/20240304210429_837.pdf

周从亚, 黄涛, 顾佳慧, 李黄倩玉, 史录文, 管晓东. 2003–2020年中国仿制药上市和新药市场独占期研究[J]. 中国药学(英文版), 2024, 33(1): 57-62.

Congya Zhou, Tao Huang, Jiahui Gu, Huangqianyu Li, Luwen Shi, Xiaodong Guan. Generic development and market exclusivity period in China: an analysis from 2003 to 2020[J]. Journal of Chinese Pharmaceutical Sciences, 2024, 33(1): 57-62.

图/表 1

参考文献 15

[1]	Kesselheim, A.S.; Sinha, M.S.; Avorn, J. Determinants of market exclusivity for prescription drugs in the United States. JAMA Intern. Med. 2017, 177, 1658.
[2]	Gunter, S.J.; Kesselheim, A.S.; Rome, B.N. Market exclusivity and changes in competition and prices associated with the US food and drug administration unapproved drug initiative. JAMA Intern. Med. 2021, 181, 1124–1126.
[3]	Nguyen, N.X.; Sheingold, S.H.; Tarazi, W.; Bosworth, A. Effect of competition on generic drug prices. Appl. Health Econ. Health Policy. 2022, 20, 243–253.
[4]	Choudhry, N.K.; Denberg, T.D.; Qaseem, A. Improving adherence to therapy and clinical outcomes while containing costs: opportunities from the greater use of generic medications: best practice advice from the clinical guidelines committee of the American college of physicians. Ann. Intern. Med. 2016, 164, 41–49.
[5]	National Medical Products Administration the Draft of Implementation Measures on Drug Trial Data Protection. 2018. This article can be found online at https://www.nmpa.gov.cn/xxgk/zhqyj/zhqyjyp/20180426171801468.html
[6]	National Medical Products Administration & State Intellectual Property Office Implementation measures for the early resolution mechanism of drug patent disputes. 2021. This article can be found online at https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20210703223942131.html
[7]	The Center for Drug Evaluation of National Medical Product Administration. This article can be found online at https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d.
[8]	Insight-China Pharma Database. This article can be found online at https://db.dxy.cn/v5.
[9]	Menet database. This article can be found online at https://www.menet.com.cn/.
[10]	WHOCC - ATC/DDD Index. WHOCC 2020. This article can be found online at https://www.whocc.no/atc_ddd_index/.
[11]	Rome, B.N.; Lee, C.C.; Kesselheim, A.S. Market exclusivity length for drugs with new generic or biosimilar competition, 2012-2018. Clin. Pharmacol. Ther. 2021, 109, 367–371.
[12]	Li, X.Y.; Yang, Y. The drug lag issue: a 20-year review of China. Investig. New Drugs. 2021, 39, 1389–1398.
[13]	Luo, X.X.; Yang, L.N.; Du, X.; Yang, J.S.; Qian, F.; Yang, Y. Analysis of patent and regulatory exclusivity for novel agents in China and the United States: a cohort study of drugs approved between 2018 and 2021. Clin. Pharmacol. Ther. 2022, 112, 335–343.
[14]	Lexchin, J. Market exclusivity time for top selling originator drugs in Canada: a cohort study. Value Health. 2017, 20, 1139–1142.
[15]	Wang, B.; Liu, J.; Kesselheim, A.S. Variations in time of market exclusivity among top-selling prescription drugs in the United States. JAMA Intern. Med. 2015, 175, 635–637.

2003–2020年中国仿制药上市和新药市场独占期研究

Generic development and market exclusivity period in China: an analysis from 2003 to 2020

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 1

参考文献 15

相关文章 8

编辑推荐

Metrics

本文评价

[1]	刘文夏, 马俊, 杨照, 江滨. 中国仿制药替代影响因素分析——基于"4 + 7"带量采购精神科用药患者角度[J]. 中国药学(英文版), 2023, 32(4): 317-321.
[2]	杨东升, 魏宁漪, 牛剑钊, 许鸣镝. 治疗等效性评价代码介绍及其对我国仿制药参比制剂选择的影响[J]. 中国药学(英文版), 2022, 31(8): 646-651.
[3]	谢英, 战寒秋, 朱晓虹, 李源, 田如意, 张静, 陈姗姗, 赵艳玲. 恩替卡韦仿制药与原研药治疗慢性乙型肝炎的疗效及依从性的多中心队列研究[J]. 中国药学(英文版), 2021, 30(12): 986-993.
[4]	聂玉瑶, 王贺, 周林光, 史录文, 江滨. 中国药师对仿制药认知的调查研究[J]. 中国药学(英文版), 2020, 29(5): 364-368.
[5]	杨东升, 马玲云, 牛剑钊, 许鸣镝. 美国授权仿制药应用简介[J]. 中国药学(英文版), 2019, 28(6): 439-445.
[6]	杨东升, 马玲云, 牛剑钊, 许鸣镝. 美国国家药品编码应用简介[J]. 中国药学(英文版), 2019, 28(3): 203-208.
[7]	严妍, 李玲, 李蕊, 于文君, 韩毅, 马玉奎, 李妍. 二甲双胍原研制剂格华止?与一种仿制制剂在大鼠模型中药代动力学和药效学比较[J]. 中国药学(英文版), 2019, 28(2): 134-142.
[8]	牛剑钊, 杨东升, 许鸣镝. 欧盟仿制药参比制剂检索与确认简介[J]. 中国药学(英文版), 2018, 27(11): 805-812.